Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 473

1.

The Evolutionary Origins of Recurrent Pancreatic Cancer.

Sakamoto H, Attiyeh MA, Gerold JM, Makohon-Moore AP, Hayashi A, Hong J, Kappagantula R, Zhang L, Melchor JP, Reiter JG, Heyde A, Bielski CM, Penson AV, Gonen M, Chakravarty D, O'Reilly EM, Wood LD, Hruban RH, Nowak MA, Socci ND, Taylor BS, Iacobuzio-Donahue CA.

Cancer Discov. 2020 Mar 19. pii: CD-19-1508. doi: 10.1158/2159-8290.CD-19-1508. [Epub ahead of print]

2.

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.

Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS.

Prostate. 2020 Mar 9. doi: 10.1002/pros.23968. [Epub ahead of print]

PMID:
32153047
3.

Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

O'Reilly EM, Ferrone C.

J Clin Oncol. 2020 Mar 2:JCO1903318. doi: 10.1200/JCO.19.03318. [Epub ahead of print] No abstract available.

PMID:
32119598
4.

Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes.

Salem M, Kadakia K, Trufan S, Hwang J, Nazemzadeh R, Jagosky M, Worrilow W, Coley H, Al Hallak M, Gower N, Philip P, O'Reilly E.

Ann Oncol. 2019 Jul;30 Suppl 4:iv79-iv80. doi: 10.1093/annonc/mdz155.289. Epub 2019 Dec 4. No abstract available.

5.

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall M, Park J, Hochhauser D, Arnold D, Oh D, Reinacher-Schick A, Tortora G, Algül H, O'Reilly E, McGuinness D, Cui K, Schlienger K, Locker G, Kindler H.

Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. No abstract available.

6.

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes.

Reni M, Riess H, O'Reilly E, Santoro A, Park J, Bekaii-Saab T, Tempero M, Shan Y, Macarulla T, Van Cutsem E, Noel M, Berlin J, Biankin A, Dhani N, Frassineti G, Goldstein D, Romano A, Bruchec YL, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. No abstract available.

7.

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial.

Reni M, Winter J, Tortora G, Pelzer U, Riess H, Chang H, O'Reilly E, Oh D, Diaz IA, Milella M, Bendell J, Garlipp B, Tempero M, Macarulla T, Van Cutsem E, Berlin J, Goldstein D, Lu B, Jeanes J, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. No abstract available.

8.

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.

Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B.

Front Oncol. 2020 Jan 31;10:41. doi: 10.3389/fonc.2020.00041. eCollection 2020.

9.

An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.

Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM.

JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]

PMID:
32053139
10.

Augmented exercise in hospital improves physical performance and reduces negative post hospitalization events: a randomized controlled trial.

McCullagh R, O'Connell E, O'Meara S, Dahly D, O'Reilly E, O'Connor K, Horgan NF, Timmons S.

BMC Geriatr. 2020 Feb 7;20(1):46. doi: 10.1186/s12877-020-1436-0.

11.

Asymmetric Construction of Alkaloids by Employing a Key ω-Transaminase Cascade.

Taday F, Ryan J, Argent SP, Caprio V, Maciá B, O'Reilly E.

Chemistry. 2020 Feb 5. doi: 10.1002/chem.202000067. [Epub ahead of print]

PMID:
32022300
12.

Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.

Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, Jordan E, El Dika I, Kemel Y, Ladanyi M, Robson ME, O'Reilly EM, Abou-Alfa GK.

Cancer. 2020 Feb 3. doi: 10.1002/cncr.32740. [Epub ahead of print]

PMID:
32012241
13.

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP.

J Clin Oncol. 2020 Jan 24:JCO1902931. doi: 10.1200/JCO.19.02931. [Epub ahead of print]

PMID:
31976786
14.

Reply to nutritional support in pancreatic cancer.

Moffat GT, Epstein AS, O'Reilly EM.

Cancer. 2020 Jan 14. doi: 10.1002/cncr.32712. [Epub ahead of print] No abstract available.

PMID:
31943151
15.

Substitution of sugar-sweetened beverages for other beverages and the risk of developing coronary heart disease: Results from the Harvard Pooling Project of Diet and Coronary Disease.

Keller A, O'Reilly EJ, Malik V, Buring JE, Andersen I, Steffen L, Robien K, Männistö S, Rimm EB, Willett W, Heitmann B.

Prev Med. 2020 Feb;131:105970. doi: 10.1016/j.ypmed.2019.105970. Epub 2019 Dec 26.

PMID:
31883872
16.

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes.

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.

Nature. 2020 Jan;577(7789):E1. doi: 10.1038/s41586-019-1839-2.

PMID:
31822847
17.

Biocatalytic cascades go viral.

O'Reilly E, Ryan J.

Science. 2019 Dec 6;366(6470):1199-1200. doi: 10.1126/science.aaz7376. No abstract available.

PMID:
31806802
18.

Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis.

O'Reilly ÉJ, Bjornevik K, Furtado JD, Kolonel LN, Le Marchand L, McCullough ML, Stevens VL, Shadyab AH, Snetselaar L, Manson JE, Ascherio A.

Neurology. 2020 Feb 25;94(8):e811-e819. doi: 10.1212/WNL.0000000000008676. Epub 2019 Dec 3.

PMID:
31796528
19.

How Relevant Is Pre-operative Obstructive Sleep Apnoea in the Asymptomatic Bariatric Surgery Patient?

O'Reilly E, Doherty L, O'Boyle C.

Obes Surg. 2020 Mar;30(3):969-974. doi: 10.1007/s11695-019-04291-8.

PMID:
31758473
20.

Impact of a transitions of care pilot service established by pharmacy residents within an academic medical center.

O'Reilly EA, Kuszmaul AK, Carter AM, Kreft KN, Spencer CA.

J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):87-92.e2. doi: 10.1016/j.japh.2019.09.018. Epub 2019 Nov 14.

PMID:
31735651
21.

Amorphous solid dispersion of ibuprofen: A comparative study on the effect of solution based techniques.

Ziaee A, O'Dea S, Howard-Hildige A, Padrela L, Potter C, Iqbal J, Albadarin AB, Walker G, O'Reilly EJ.

Int J Pharm. 2019 Dec 15;572:118816. doi: 10.1016/j.ijpharm.2019.118816. Epub 2019 Oct 31.

PMID:
31678527
22.

PD-1 Blockade in Advanced Adrenocortical Carcinoma.

Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL.

J Clin Oncol. 2020 Jan 1;38(1):71-80. doi: 10.1200/JCO.19.01586. Epub 2019 Oct 23.

PMID:
31644329
23.

Incidence of Asymptomatic Chiari Malformation

O’Reilly EM, Torreggiani W.

Ir Med J. 2019 Aug 1;112(7):972.

PMID:
31642646
24.

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.

O'Reilly EM, Hechtman JF.

Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40. doi: 10.1093/annonc/mdz385.

25.

Ge1-xSnx alloys: Consequences of band mixing effects for the evolution of the band gap Γ-character with Sn concentration.

Eales TD, Marko IP, Schulz S, O'Halloran E, Ghetmiri S, Du W, Zhou Y, Yu SQ, Margetis J, Tolle J, O'Reilly EP, Sweeney SJ.

Sci Rep. 2019 Oct 1;9(1):14077. doi: 10.1038/s41598-019-50349-z.

26.

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators.

Ann Oncol. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406.

27.

Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Lohrmann C, O'Reilly EM, O'Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):7014-7023. doi: 10.1158/1078-0432.CCR-18-3667. Epub 2019 Sep 20.

PMID:
31540979
28.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Oct 10;:.

PMID:
31486832
29.

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK.

Cancer. 2019 Dec 15;125(24):4426-4434. doi: 10.1002/cncr.32463. Epub 2019 Aug 27.

PMID:
31454426
30.
31.

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC.

Ann Surg Oncol. 2019 Dec;26(13):4489-4497. doi: 10.1245/s10434-019-07685-1. Epub 2019 Aug 15.

PMID:
31418130
32.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

J Clin Oncol. 2019 Oct 10;37(29):2620-2631. doi: 10.1200/JCO.19.01019. Epub 2019 Aug 13.

33.

Pancreatic cancer-A disease in need: Optimizing and integrating supportive care.

Moffat GT, Epstein AS, O'Reilly EM.

Cancer. 2019 Nov 15;125(22):3927-3935. doi: 10.1002/cncr.32423. Epub 2019 Aug 5. Review.

PMID:
31381149
34.

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.

Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM.

Cancer Med. 2019 Sep;8(11):5148-5157. doi: 10.1002/cam4.2425. Epub 2019 Jul 26.

35.

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1588. [Epub ahead of print]

PMID:
31318392
36.

Models for pharmacist-delivered tobacco cessation services: a systematic review.

O'Reilly E, Frederick E, Palmer E.

J Am Pharm Assoc (2003). 2019 Sep - Oct;59(5):742-752. doi: 10.1016/j.japh.2019.05.022. Epub 2019 Jul 12. Review.

PMID:
31307963
37.

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Noel M, O'Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B, Yin D, Joh T, Jacobs IA, Taylor CT, Lowery MA.

Invest New Drugs. 2019 Jul 12. doi: 10.1007/s10637-019-00830-3. [Epub ahead of print]

PMID:
31297636
38.

Tumour lineage shapes BRCA-mediated phenotypes.

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.

Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10. Erratum in: Nature. 2019 Dec 11;:.

39.

Impact of polymeric excipient on cocrystal formation via hot-melt extrusion and subsequent downstream processing.

Karimi-Jafari M, Ziaee A, Iqbal J, O'Reilly E, Croker D, Walker G.

Int J Pharm. 2019 Jul 20;566:745-755. doi: 10.1016/j.ijpharm.2019.06.031. Epub 2019 Jun 15.

PMID:
31212053
40.

A mixed methods analysis of patients' advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC).

Agarwal R, Shuk E, Romano D, Genoff M, Li Y, O'Reilly EM, Breitbart W, Volandes AE, Epstein AS.

Support Care Cancer. 2020 Mar;28(3):1109-1119. doi: 10.1007/s00520-019-04910-1. Epub 2019 Jun 13.

PMID:
31197540
41.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

42.

Impact of pharmacist intervention on glucagon prescribing patterns in an outpatient internal medicine teaching clinic.

O'Reilly EA, Cross LV, Hayes JS, Kubiak NT.

J Am Pharm Assoc (2003). 2019 May 16. pii: S1544-3191(19)30152-9. doi: 10.1016/j.japh.2019.04.009. [Epub ahead of print]

PMID:
31104980
43.

Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution.

Creasy JM, Goldman DA, Gonen M, Dudeja V, O'Reilly EM, Abou-Alfa GK, Cercek A, Harding JJ, Balachandran VP, Drebin JA, Allen PJ, Kingham TP, D'Angelica MI, Jarnagin WR.

HPB (Oxford). 2019 Nov;21(11):1541-1551. doi: 10.1016/j.hpb.2019.03.370. Epub 2019 Apr 23.

PMID:
31027875
44.

Particle engineering of excipients: A mechanistic investigation into the compaction properties of lignin and [co]-spray dried lignin.

Solomon S, Ziaee A, Giraudeau L, O'Reilly E, Walker G, Albadarin AB.

Int J Pharm. 2019 May 30;563:237-248. doi: 10.1016/j.ijpharm.2019.03.061. Epub 2019 Mar 29.

PMID:
30935917
45.

Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM.

Cancer Treat Rev. 2019 May;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. Epub 2019 Mar 22. Review.

PMID:
30927677
46.

Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis.

Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A.

Neurology. 2019 Apr 30;92(18):e2089-e2100. doi: 10.1212/WNL.0000000000007401. Epub 2019 Mar 29.

PMID:
30926684
47.

Use of Negative Control Exposure Analysis to Evaluate Confounding: An Example of Acetaminophen Exposure and Attention-Deficit/Hyperactivity Disorder in Nurses' Health Study II.

Liew Z, Kioumourtzoglou MA, Roberts AL, O'Reilly ÉJ, Ascherio A, Weisskopf MG.

Am J Epidemiol. 2019 Apr 1;188(4):768-775. doi: 10.1093/aje/kwy288.

PMID:
30923825
48.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
49.

An immunoturbidimetric assay for bovine haptoglobin.

Brady N, O'Reilly EL, McComb C, Macrae AI, Eckersall PD.

Comp Clin Path. 2019;28(1):21-27. doi: 10.1007/s00580-018-2863-6. Epub 2018 Nov 14.

50.

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS.

JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00134. Epub 2019 Jan 14.

Supplemental Content

Loading ...
Support Center